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Introduction
Numerous non-infectious processes can produce res-
piratory symptoms and new pulmonary inﬁ  ltrates with 
systemic inﬂ  ammatory signs and symptoms with fever, 
leukocytosis and acute phase reactants that can be eas-
ily confused with bacterial pneumonia. Typically, Gram 
stains of respiratory secretions are often unavailable 
or are diﬃ   cult to evaluate, and microbiological culture 
reports take 24 to 48 hours. A negative sputum culture in 
a patient suspected of having community-acquired pneu-
monia (CAP) does not rule out the possibility of severe 
bacterial infection.
Th  e standard methods used today to diagnose CAP 
have not changed appreciably since Pasteur and Sternberg 
ﬁ   rst cultured pneumococci from sputum in 1881 and 
Christian Gram ﬁ   rst applied his now famous stain to 
examine sputum specimens 5 years later. Acquiring high-
quality sputum samples for culture and interpreting these 
culture results remain elusive clinical challenges. Th  ere 
are no unequivocal clinical predictors of disease severity, 
although many clinical scoring systems currently exist for 
this purpose. No generally agreed criteria exist for deter-
mining which patients should be admitted to the hospital 
medical service or to the intensive care unit (ICU). Given 
these areas of uncertainty in clinical decision-making, a 
concerted eﬀ  ort has been undertaken to develop reliable 
and practical biomarkers for the diagnosis, risk prediction 
and management of CAP.
To be helpful in routine clinical practice, a biomarker 
should provide additional actionable information – not 
already available by standard methods – that accomplishes 
at least one or more of the following: assists in establish-
ing a rapid and reliable diagnosis; provides an indication 
of prognosis; selects those patients most likely to beneﬁ  t 
from a speciﬁ  c intervention; reﬂ  ects the eﬃ   cacy or lack of 
eﬃ   cacy of speciﬁ  c interventions; warns in advance of dis-
ease progression; exhibits a large amplitude of variation; 
and does not show an exhaustion or fatigue phenomenon, 
meaning that during prolonged and successive infections 
its levels remain elevated and always responsive to the 
infectious stimulus [1].
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Abstract
In patients with community-acquired pneumonia, 
traditional criteria of infection based on clinical signs 
and symptoms, clinical scoring systems, and general 
infl  ammatory indicators (for example, leukocytosis, 
fever, C-reactive protein and blood cultures) are often 
of limited clinical value and remain an unreliable 
guide to etiology, optimal therapy and prognosis. 
Procalcitonin is superior to other commonly used 
markers in its specifi  city for bacterial infection 
(allowing alternative diagnoses to be excluded), as 
an indicator of disease severity and risk of death, 
and mainly as a guide to the necessity for antibiotic 
therapy. It can therefore be viewed as a diagnostic, 
prognostic, and perhaps even theragnostic test. It 
more closely matches the criteria for usefulness than 
other candidate biomarkers such as C-reactive protein, 
which is rather a nonspecifi  c marker of acute phase 
infl  ammation, and proinfl  ammatory cytokines such as 
plasma IL-6 levels that are highly variable, cumbersome 
to measure, and lack specifi  city for systemic infection. 
Elevated levels of pro-adrenomedullin, copeptin (which 
is produced in equimolar amounts to vasopressin), 
natriuretic peptides and cortisol are signifi  cantly related 
to mortality in community-acquired pneumonia, as 
are other prohormones such as pro-atrial natriuretic 
peptide, coagulation markers, and other combinations 
of infl  ammatory cytokine profi  les. However, all 
biomarkers have weaknesses as well as strengths. None 
should be used on its own; and none is anything more 
than an aid in the exercise of clinical judgment based 
upon a synthesis of available clinical, physiologic and 
laboratory features in each patient.
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Within the context of clinical trials, a biomarker might 
also prove useful in identifying patients suitable for enroll-
ment into a clinical study. Biomarkers might deﬁ  ne the 
nature of their disease or its severity, provide insights into 
the drug’s mechanism of action, establish which groups 
of patients within a trial population experience the great-
est beneﬁ  t, or serve as a surrogate for long-term outcome 
such as mortality. To be of greatest practical value, a can-
didate assay for a biomarker needs to provide quantita-
tive information that is both reliable and reproducible. 
Moreover, the ideal biomarker measurement should be 
rapid, easy and inexpensive to perform.
Th   e present brief review examines the currently avail-
able biomarkers, and those under development, and asks 
whether they add suﬃ   ciently valuable, explanatory infor-
mation over traditional diagnostic and prognostic criteria 
for CAP to warrant their routine use and improve patient 
management. We summarize the existing evidence about 
the utility of markers that are already available clinically. A 
substantial number of biomarker assays are in the devel-
opment process, and some of these assays are likely to 
assume an increasingly important role in clinical manage-
ment of CAP in the future.
Search strategy
A Medline and PubMed search of relevant medical lit-
erature in the English language published in the past 15 
years was performed using search terms including com-
munity-acquired pneumonia, clinical scoring systems for 
pneumonia, biomarkers for infection and inﬂ  ammation, 
prognostic factors, pneumonia severity indicators, and 
surrogate markers of pneumonia severity. Th  e papers 
chosen for study were reviewed by one or both of the 
authors for evidence and consistency of the data. Older 
literature and existing meta-analyses or other systematic 
reviews of the topic were included when they added addi-
tional signiﬁ  cant insights and evidence.
Table 1 summarizes the discusses biomarkers.
Markers that may aid diagnosis
Procalcitonin, C-reactive protein and leukocyte count
Th   e diagnostic and prognostic accuracy of clinical signs 
and symptoms and a range of laboratory markers were 
recently assessed in a planned post hoc analysis of 545 
patients with suspected lower respiratory tract infection 
admitted to the emergency department [2]. In a receiver 
operating characteristic analysis to determine the diag-
nostic accuracy for CAP, the area under the curve of a 
clinical model including fever, cough, sputum produc-
tion, abnormal chest auscultation and dyspnea was 0.79. 
Including values for procalcitonin (PCT) and highly sen-
sitive C-reactive protein (CRP) increased the area under 
the curve to 0.92, which was signiﬁ  cantly better than the 
areas under the curve for PCT, CRP and clinical signs and 
symptoms alone (Figure 1). Th   e contribution to diagnos-
tic reliability made by PCT was substantially greater than 
that made by CRP, which in turn performed better than 
the total leukocyte count. Clinical criteria such as sputum 
production and physical examination with chest auscul-
tation were surprisingly poor predictors for the diagno-
sis of CAP. Th   e added value of the PCT biomarker as a 
clinical decision-making tool is evidenced in the present 
study and many other studies involving PCT measure-
ment [3-9].
Table 1. Table of biomarkers
  Widely available biomarkers  Potential future biomarkers
Biomarkers of infl  ammation  Tumor necrosis factor alpha  IL-1β
 Lactate  IL-6
   IL-10
Biomarkers of coagulation  Activated partial thromboplastin time  Protein C 
 Platelets  D-dimer 
 Fibrinogen  Thrombin–antithrombin  complexes
  Disseminated intravascular coagulation scores  Prothrombin fragment 1.2
    Activated partial thromboplastin time waveform analysis
Biomarkers of infection  C-reactive protein  Adrenomedullin
 Procalcitonin  Pro-adrenomedullin
  Blood urea nitrogen  B-type natriuretic peptide
  Leukocytes  Triggering receptor expressed on myeloid cells-1 (soluble 
    triggering receptor expressed on myeloid cells-1)
  Endotoxin  High mobility group box-1
 PCR 
Biomarkers of stress  Cortisol  Copeptin
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PCT is a pre-pro-peptide precursor of the thyroid hor-
mone calcitonin [10]. Mature calcitonin is named after its 
mild and transient hypocalcemic eﬀ  ect and was originally 
thought to play an important role in calcium homeostasis. 
Th  yroidectomy in humans has no important pathologic 
consequences, however, provided thyroid hormone is 
replaced: calcium homeostasis remains intact, suggesting 
that the function of the mature calcitonin in humans is no 
longer essential [11].
Circulating levels of the precursor hormone PCT, 
derived primarily from nonthyroidal tissues, can rise 
several thousand times above normal in various inﬂ  am-
matory conditions, but most notably in bacterial infec-
tion [4]. In diﬀ  erentiating bacterial infection from non-
infective causes of inﬂ  ammation in hospitalized patients, 
a meta-analysis concluded that PCT was both more sensi-
tive (85% vs. 78%) and more speciﬁ  c (83% vs. 60%) com-
pared with CRP. PCT was also more sensitive in diﬀ  eren-
tiating between a bacterial etiology and a viral etiology [7].
Use of PCT as a biomarker is increasingly common in 
Europe, not only in the diagnosis of sepsis but also in less 
severe infections such as CAP. Th   e value of PCT depends 
on the clinical setting in which it is used and, crucially, 
on the sensitivity of the assay. Th   e Kryptor assay (Brahms, 
Hennigsdorf, Germany) has a functional sensitivity of 
0.06 μg/l (between threefold and 10-fold above the nor-
mal mean value). Th  is assay reliably detects even mild/
moderately elevated PCT [12,13]. In routine practice, 
results are available within 1 hour. Such assay devices are 
now widely available in many larger hospitals and clinical 
laboratories. A rapid bedside test that can also be used in 
smaller laboratories and in general practice is currently 
in development. Th   e Food and Drug Administration has 
approved the more sensitive assay in the USA; however, 
approval has only been given for the indication of pro-
gression from severe sepsis to septic shock.
One particularly important role of PCT measurement 
appears to be in allowing certain diagnoses to be excluded. 
A PCT value below a speciﬁ  c threshold level (according to 
most studies, 0.25 μg/l) makes it very unlikely a patient has 
severe CAP [7]. It should be noted that PCT levels may be 
high when measured in patients with non-infectious, sys-
temic inﬂ  ammatory states such as severe trauma, recent 
surgery, or burns [14]. In the absence of infection, however, 
PCT levels generally decline to below 1 ng/ml (or 1 μg/l) 
within 48 hours, pointing to the importance of repeated 
measurements of PCT with high-sensitivity assays [15]. 
Furthermore, it must be acknowledged that the extent of 
the inﬂ  ammatory response attributable to infection (that 
is, the signal) is often limited – due to the relatively low 
virulence of many of the causative microorganisms found 
in ventilator-associated pneumonia, as compared with the 
omnipresent underlying systemic inﬂ  ammatory response 
syndrome already existing in every intubated, critically 
ill patient (that is, the noise). Th   e resulting lower signal-
to-noise ratio in ventilator-associated pneumonia limits 
the diagnostic accuracy of biomarkers such as PCT in 
ventilator-associated pneumonia. Serial measurements of 
PCT over time are informative, and trend lines of absolute 
values are more useful than the percentage decrease from 
baseline values.
In contrast to PCT, the routine laboratory tests for CRP 
and the white cell count lack speciﬁ  city for bacterial infec-
tion; a high CRP could be due to numerous other inﬂ  am-
matory conditions or ischemic injury including myo-
cardial infarction. Administration of steroids does not 
diminish the value of PCT [16]. For CRP, recent data sug-
gest that steroids do not inﬂ  uence CRP levels in patients 
with CAP [17].
A wealth of publications in the medical literature over 
the past 10 years support the diagnostic utility of PCT for 
acute systemic bacterial infections [18-22]; yet in a recent 
meta-analysis, Tang and colleagues questioned the valid-
ity of PCT in diﬀ  erentiating sepsis from non-infectious 
causes of systemic inﬂ  ammatory response syndrome [23]. 
Th  e  diﬀ  erences between this study and the meta-analysis 
Figure 1. Diagnostic accuracy of diff  erent biomarkers 
for community-acquired pneumonia. Receiver operating 
characteristics (ROC) curves for diagnostic accuracy to predict 
radiographically suspected community-acquired pneumonia (CAP) 
including other non-infectious diagnoses initially diagnosed as 
CAP plus patients without a clinically relevant bacterial etiology of 
CAP. Values show areas under the ROC curve with 95% confi  dence 
intervals. CRP, C-reactive protein; PCT, procalcitonin.
Christ-Crain and Opal Critical Care 2010, 14:203 
http://ccforum.com/content/14/1/203Page 4 of 11
of Simon and colleagues can mainly be explained by dif-
ferent inclusion criteria [7]. As pointed out in a response 
to this meta-analysis from Reinhart and Brunkhorst [24], 
the search strategy and strict inclusion criteria used in 
the meta-analysis can be questioned, and it is debatable 
whether exclusion of abdominal sepsis patient and septic 
shock patient populations is appropriate.
Other studies found a good diagnostic performance for 
CRP [25,26] and found better diagnostic accuracy for CRP 
as compared with PCT [27]. Importantly, however, it must 
be pointed out that all observational studies and meta-
analyses are susceptible to potential publication selection 
bias. Only randomized controlled intervention studies 
have the potential to resolve the controversial topic (see 
section As a guide to therapy). Intervention studies in 
patients with pneumonia are only available for PCT, but 
not for CRP. Future intervention studies should focus on a 
direct head-to-head comparison of these two biomarkers.
Proinfl  ammatory cytokines
Th  e presence in the bloodstream of lipopolysaccharide, 
sometimes referred to as endotoxin, is taken by the host 
as evidence of invasion by pathogenic Gram-negative bac-
teria [28]. In point of fact, endotoxemia is quite prevalent 
even in Gram-positive sepsis or fungal sepsis. Th  e  expla-
nation for this ﬁ  nding is related to shock-induced gut 
ischemia with splanchnic hypoperfusion and increased 
intestinal permeability. Impaired mucosal barrier func-
tion is accompanied by egress of lipopolysaccharide 
found in the lumen of the gut from endogenous enteric 
Gram-negative bacteria into the systemic circulation [29]. 
Th   e host responds by releasing an array of inﬂ  ammatory 
mediators and procoagulant factors.
In principle, these factors, or the measurement of 
lipopolysaccharide itself, could constitute markers indica-
tive of severity of disease [28]. While cytokine expres-
sion and release in the circulation are common events 
in systemic inﬂ  ammatory states, however, the standard 
proinﬂ  ammatory cytokines such as TNFα, IL-1β and IL-6 
have proven to be unreliable indicators of speciﬁ  c infec-
tions such as severe CAP for a number of reasons. Th  ese 
cytokines have short serum half-lives and the blood levels 
are highly variable, transient, and nonspeciﬁ  c. IL-1 and 
TNF are present in very low concentrations (picomolar 
levels) in most infectious disease states and are therefore 
diﬃ   cult to measure [30].
Of the myriad of cytokines and chemokines that can be 
measured in the circulation during acute inﬂ  ammation, 
IL-6 may be the best studied and most valuable as a prog-
nostic indicator [31]. Multiplex assays now permit simul-
taneous measurement of multiple cytokines with relative 
ease [32]. A paper by Kellum and colleagues using a large 
database from the GenIMS study of CAP demonstrated a 
clear correlation between the ratio of IL-6 to IL-10, and 
the risk of mortality in patients with CAP [33]. Patients 
with elevated levels of both IL-6 and IL-10 had a risk of 
death more than 20 times higher than patients with low 
levels of both cytokines (P <0.001).
In a prospective cohort study investigating all-cause 
and cause-speciﬁ   c 1-year mortality in CAP survivors 
[34], higher IL-6 and IL-10 concentrations at hospital dis-
charge were associated with an increased risk of death, 
which gradually fell over time. For each log-unit increase, 
the range of adjusted hazard ratios for IL-6 was 1.02 to 
1.46 (P <0.0001), and the range for IL-10 was 1.17 to 1.44 
(P = 0.01). High IL-6 concentrations were particularly 
associated with death due to cardiovascular disease, can-
cer, infections, and renal failure (P = 0.008). Th  ese  inves-
tigations pointed out that cytokine levels might actually 
be more predictive of adverse outcome when measured 
at the end of hospitalization rather than the traditional 
measurement of cytokines in the early phases of seeking 
medical attention. Th   e same has been shown for CRP [35].
Triggering receptor expressed on myeloid cells-1, high 
mobility group box-1 and other potential markers
Triggering receptor expressed on myeloid cells-1 is upregu-
lated by microbial products [36]. Soluble triggering recep-
tor expressed on myeloid cells-1 in bronchoalveolar lavage 
ﬂ  uid accurately identiﬁ  es bacterial or fungal pneumonia 
in mechanically ventilated patients, and is superior in this 
regard to clinical ﬁ  ndings or other laboratory values. Such 
lavage is not appropriate, however, in the routine care of 
patients with severe CAP. In this severe CAP setting, meas-
urement of soluble triggering receptor expressed on mye-
loid cells-1 in plasma or serum has proved unhelpful as a 
guide to either etiology or outcome [37].
High mobility group box-1 nonhistone nucleoprotein is 
released from damaged cells and during systemic inﬂ  am-
mation, and has proven to be a promising, late marker of 
disease severity. Circulating blood levels of high mobil-
ity group box-1 are high and remain high in patients with 
severe sepsis [38]. In a study in CAP patients, high mobil-
ity group box-1 levels were frequently measurable, even at 
the time of hospital discharge, and were not helpful as a 
long-term prognostic indicator [39]. Further study of this 
remarkable plasma protein is warranted in the future to 
determine its practical clinical value in the management 
of severe CAP.
Other biomarkers are continuously being discovered in 
animal and human experimental pneumonia models, as 
well as in ongoing clinical investigations. Many of these 
markers will undoubtedly be proposed for the diagnosis 
and management of CAP in the future.
Early microbial diagnosis and susceptibility testing
Molecular biomarkers for rapid microbial diagnosis using 
real-time PCR and similar nucleic acid-based, nonculture 
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methods are now available in some centers and will soon 
become routinely available in the clinic [40,41]. Such 
techniques should facilitate early detection of bacteremia, 
should speed precise diagnosis of microbial pathogens, 
and should allow rapid initiation of appropriately targeted 
antibiotic therapy.
A recent study demonstrated that the availability of 
real-time PCR could distinguish Staphylococcus aureus 
from coagulase-negative staphylococci and could detect 
methicillin resistance in 90 minutes [42]. Th  is  molecular 
technique permits early diagnosis and appropriate ther-
apy, and use of the procedure will probably become the 
standard of care in the next few years.
Indicators of prognosis
CAP is the leading cause of death from infection in west-
ern countries [43]. Ideally, the management strategy 
and nature of the intervention for CAP (including the 
need for hospitalization and admission to intensive care) 
would be tailored to the severity of disease and mortal-
ity risk in the individual patient. In the emerging era of 
personalized medicine, with rapid diagnosis and thera-
peutic strategies based upon unique patient characteris-
tics, focused care will be directed by advanced systems 
biology to minimize potential harm and to maximize the 
eﬃ   cacy of each intervention [44]. Th   ese great expecta-
tions are predicated upon the widely held belief that 
rapid access to improved biomarkers will permit this 
type of high-level individualized care. Such biomark-
ers will need to demonstrate superiority over standard 
clinical criteria alone (that is, clinical scoring systems) 
in adequately powered prospective studies. Examples 
of the clinical value of such scoring systems will be dis-
cussed in the following paragraphs.
Comparisons between biomarkers and global severity 
scoring systems for community-acquired pneumonia
Biomarkers for CAP are often compared with global 
measures of disease severity using clinical scoring sys-
tems. Developed by analyzing data from over 14,000 cases 
of CAP, the pneumonia severity index (PSI) uses a two-
step algorithm to divide patients into ﬁ  ve classes based 
on the risk of death within 30 days [45]. Th   e index, which 
integrates data about age and coexisting disease with val-
ues on a range of clinical and laboratory ﬁ  ndings, was vali-
dated among more than 40,000 cases in the Pneumonia 
Patient Outcomes Research Team cohort. Th   e PSI poten-
tially overemphasizes the importance of age, however, 
and inter-observer variability may lead to misclassiﬁ  ca-
tion of patients, especially at the more severe end of the 
spectrum. Th   e PSI has the disadvantage of dichotomizing 
continuous variables into normal/abnormal (to make it 
more user-friendly), and yet it is still complex enough to 
discourage routine adoption.
Th  e CURB-65 score is a simpler severity score devel-
oped by the British Th   oracic Society, based on only ﬁ  ve 
factors (confusion, urea nitrogen, respiratory rate, blood 
pressure, and age 65 and older). It is an easily measured 
alternative to the PSI and is widely used in Europe [46].
Logistical regression analysis of data from the Australian 
CAP study has led to the development of the SMART-
COP method of scoring severe pneumonia [47]. Th  e 
features statistically signiﬁ  cantly associated with receipt 
of invasive respiratory or vasopressor support were low 
systolic blood pressure, multilobar chest radiography 
involvement, low albumin level, high respiratory rate, 
tachycardia, confusion, poor oxygenation, and low arte-
rial pH: SMART-COP. A SMART-COP score ≥3 points 
identiﬁ  ed 92% of patients who received invasive respira-
tory or vasopressor support, including 84% of patients 
who did not need immediate admission to the ICU.
Finally, the updated prediction model from the 2007 
Infectious Disease Society of America–American Th  oracic 
Society guidelines for management of CAP [48] is also 
widely used. Th   is scores pneumonia severity based on the 
presence of two major criteria (need for mechanical venti-
lation or therapeutic vasopressors) or several minor crite-
ria. Th   e presence of at least one of these major criteria or at 
least three of the minor criteria should prompt admission 
to the ICU.
Procalcitonin, other hormokines and cortisol as prognostic 
indicators in community-acquired pneumonia
During inﬂ   ammation and infection, certain hormones 
behave like cytokines: hence the term hormokines, of which 
PCT is the prototype. Others that have attracted attention 
as potentially useful prognostic markers include adrenom-
edullin (ADM), the natriuretic peptides (atrial natriuretic 
peptide and B-type natriuretic peptide) and copeptin, 
which mirrors vasopressin. Assays for proADM, pro-atrial 
natriuretic peptide and B-type natriuretic peptide have 
recently become commercially available in Europe. Clinical 
experience with these peptide precursor molecules are lim-
ited to date but so far compare favorably with PCT [49-51]. 
Consideration of the potential value of measuring these 
peptides, along with that of an assay for cortisol, which has 
long been readily available, is therefore timely.
PCT is a more powerful guide to prognosis in pneu-
monia than several more commonly used biomark-
ers. In the post hoc analysis of data from 545 patients 
described above [2], raised PCT was signiﬁ  cantly related 
to increasing severity of CAP as assessed by the PSI. CRP 
and the leukocyte count did not show the same system-
atic relationship. Th  e prognostic value of PCT can be 
markedly increased by serial measurement. Th  e relative 
risk of mortality in the ICU was thus 1.8 for critically ill 
patients, showing PCT increases over 1 day – increasing 
to 2.8 among patients whose PCT rose over 3 days [52]. 
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Increasing CRP levels or white cell count did not predict 
mortality. In contrast, in a recent paper, CRP measured on 
admission and on day 3 after admission predicted treat-
ment failure and diﬀ  erentiated early from late treatment 
failure [53]. Persistently high levels of PCT are associated 
with worse outcome [54]. In contrast, a falling level of 
PCT, which often follows a log-linear curve with a half-
life of 20 to 24 hours, suggests a favorable outcome. Luyt 
and colleagues demonstrated that the kinetics of PCT also 
have prognostic implications in patients with ventilator-
associated pneumonia [55].
In patients with CAP, total serum cortisol levels increase 
with increasing severity of disease as assessed by the PSI 
[56]. Th   is relationship was not evident with CRP or the leu-
kocyte count. Cortisol levels in survivors were signiﬁ  cantly 
lower at baseline than those in nonsurvivors. In a receiver 
operating characteristic analysis to predict survival, the 
area under the curve for cortisol was 0.76, the same value as 
that for the PSI. PCT, CRP and the leukocyte count were all 
less predictive. In this study, measurement of free cortisol 
had no advantage over measurement of serum total cortisol 
[56]. One notable limitation of cortisol, however, is that it 
cannot be used in patients receiving steroids.
Like cortisol, copeptin mirrors the individual stress 
level – and it is most probably this reﬂ  ection of the stress 
level that enables them both to predict outcome. Copeptin 
reﬂ  ects individual stress at a higher (that is, hypotha-
lamic–pituitary) level, whereas cortisol levels mirror the 
more peripheral stress response of the adrenals [57]. In a 
cohort of 373 patients with CAP, copeptin increased with 
increasing severity of the PSI and was an independent 
predictor of outcome, in contrast to other clinical symp-
toms and ﬁ  ndings [49].
In a study of 302 patients admitted to the emergency 
department with CAP, a range of potential biomarkers was 
studied [58]. Levels of proADM (a member of the calci-
tonin gene family extensively expressed during infection) 
increased with increasing disease severity, as reﬂ  ected in 
the PSI score. Among patients who died during follow-up, 
proADM levels on admission were signiﬁ  cantly higher than 
in survivors. ProADM was more closely related to mortal-
ity than PCT, CRP or the leukocyte count, and had approxi-
mately the same prognostic accuracy as the PSI. Th  e  corre-
lation between proADM and the PSI was only around 50%, 
indicating that proADM provides information not cap-
tured in the PSI. Taking proADM into account in assessing 
mortality risk signiﬁ  cantly increased the predictive value of 
a model based on the PSI alone. Importantly, patients with 
a high proADM level were at high risk of mortality even 
when they were low risk according to the PSI.
Markers of coagulation
Activation of coagulation and concomitant downregula-
tion of anticoagulant systems and impaired ﬁ  brinolysis are 
prominent features of severe sepsis. Th   ere is an important 
interaction – mediated at least in part by protease-acti-
vated receptors – between inﬂ  ammatory mechanisms and 
coagulopathy [59]; both systems are consistently activated 
by severe infection and inﬂ  ammatory states.
Among the markers that have been suggested as pre-
dictors of adverse outcome are prothrombin fragments 
(PF1.2), thrombin–antithrombin complexes (TATc) caused 
by the complexing of thrombin with its naturally occur-
ring inhibitor, and D-dimer, a degradation product of 
cross-linked ﬁ  brin indicative not just of coagulation but 
also of ﬁ  brinolysis.
In CAP, baseline D-dimer shows a strong relation-
ship with mortality in patients with a PSI of 5 [60]. Th  e 
International Society of Th  rombosis and Hemostasis 
disseminated intravascular coagulation (DIC) score 
[61] and similar DIC scoring systems – for example, 
the modiﬁ  ed Japanese Association for Acute Medicine 
DIC score [62] – are also highly predictive of outcome 
in severe sepsis patients; the majority of these patients 
had severe pneumonia as the cause of severe sepsis [63]. 
Additionally, patients with a genetic predisposition to 
impaired ﬁ   brinolysis (elevated plasminogen activator 
inhibitor-1 levels) have a greater propensity to develop 
pneumonia [64].
Waveform analysis of activated partial thromboplastin time
Th   e presence of an abnormal biphasic transmittance wave-
form during measurement of the activated partial throm-
boplastin time (aPTT) has been found more accurate than 
either PCT or CRP in distinguishing those patients with 
severe sepsis or septic shock among a wider population 
meeting at least two criteria of systemic inﬂ  ammatory 
response syndrome [65]. Th  e biphasic waveform of clot 
generation is related to a complex of CRP and lipoproteins 
that alters the rate of change in plasma transmittance as 
clotting occurs. Th   is biphasic wave form is captured on spe-
ciﬁ  c optics systems on some aPTT machines. Th  e  biphasic 
waveform measure can also provide prognostic informa-
tion: values on days 1 to 3 following admission were signiﬁ  -
cantly more abnormal in sepsis patients who subsequently 
died than in sepsis patients who survived or in nonsepsis 
patients who died. An aPTT waveform analysis can be eas-
ily and quickly undertaken, and – although this study was 
conducted in a surgical ICU [65] – its ﬁ  ndings may have 
implications for the diagnosis of infection in patients with 
severe CAP.
A further study, conducted in 200 patients on a medico-
surgical ICU, demonstrated that combining aPTT wave-
form analysis with PCT increased its speciﬁ  city in the 
identiﬁ  cation of sepsis in acutely ill patients [66]. Of 60 
patients with an abnormal PCT (>1 ng/ml) at admission, 
40% were subsequently diagnosed with sepsis. Among 
the 30 patients who had both an abnormal PCT and an 
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abnormal aPTT waveform, 77% had sepsis. It should be 
noted that the use of aPTT waveform studies as a diagnos-
tic platform thus far have not speciﬁ  cally focused upon 
CAP patients. Th   ese reports measure the diagnostic util-
ity of biphasic wave form analysis for sepsis from many 
sources and tissue sites of severe infection.
Disseminated intravascular coagulation scores
A substantial literature links global assessment of coagu-
lation dysfunction, based on widely available laboratory 
tests, to poor prognosis. Retrospective analysis of data 
from the placebo group in the PROWESS trial of drot-
recogin alfa show a signiﬁ   cant relationship between 
an increasing International Society of Th  rombosis and 
Haemostasis DIC score (based on the prothrombin time, 
D-dimer level, ﬁ  brinogen and platelet count) and 28-day 
mortality [63]. Th   is relationship was independent of, and 
stronger than, that of age or the Acute Physiology and 
Chronic Health Evaluation II score.
In one prospective study, each point increment in the 
International Society of Th   rombosis and Hemostasis DIC 
score increased the odds ratio for 28-day mortality by 
1.25. Th   e pattern of coagulation activation may be more 
helpful than any individual parameter. Interestingly, an 
abnormal aPTT waveform correlated highly with the DIC 
score, and in 19% of patients was evident before diagno-
sis could be made on the basis of the scoring system [61]. 
Patients with severe CAP show abnormalities of coagula-
tion [67], and an absence of these markers is useful in rul-
ing out clinical sepsis.
As a guide to therapy
Despite the fact that the majority of lower respiratory tract 
infections are viral in origin, antibiotics are frequently 
prescribed, especially in patients who are critically ill (for 
example, the highest misuse of antibiotics in respiratory 
tract infections is seen in general practice) [68]. In the 
Pro-Resp trial evaluating PCT in the emergency depart-
ment, patients with lower respiratory tract infections 
were randomized to traditional antibiotic manage  ment 
or to management guided by PCT [13]. Use of antibiot-
ics was discouraged when the PCT level was <0.1 μg/l or 
<0.25 μg/l. In patients randomized to management using 
the PCT algorithm, antibiotic usage was one-half that in 
the traditionally managed group, without clinical or labo-
ratory outcome being compromised.
Although CAP is more likely to be bacterial, such 
organisms are typically identiﬁ  ed in fewer than 50% of 
cases. Delayed use of antibiotics, however, is associated 
with increased mortality [69]. In a randomized trial in this 
setting, PCT-guided therapy reduced the duration of anti-
biotic therapy from a median of 12 days to 5 days without 
compromising the overall 83% success rate of treatment 
[70] (Figure 2).
In the setting of general practice, PCT has been shown 
to reduce antibiotic exposure by 72% [71]. In a recent 
study, CRP also showed potential to reduce antibiotic pre-
scription, but to a smaller extent [72].
Genetic and proteomic markers
Th  ere are genetic factors associated with increased risk 
of contracting severe CAP. A large number of SNPs and 
haplotypes are associated with worse outcome and are 
therefore prognostic. Genomics therefore has potential as 
a source of markers relevant to the disease.
Clinically, systemic inﬂ  ammatory response syndrome 
of diﬀ   erent etiologies present in a similar way. Gene 
expression proﬁ  les in patients with systemic inﬂ  amma-
tory response syndrome arising from infection and subse-
quently leading to sepsis have been compared with those 
in patients whose systemic inﬂ  ammatory response syn-
drome was due to other causes [73]. On the Aﬀ  ymetrix 
microarray, upregulation or downregulation of several 
hundred genes distinguished between patients whose 
inﬂ   ammatory condition was caused by infection and 
those whose respiratory syndrome was non-infective in 
origin. Th  e genes that diﬀ  erentiated between etiologies 
involved four areas: innate immunity, cytokine receptors, 
T-cell diﬀ  erentiation, and regulation of protein synthesis.
Despite evidence of diﬀ  erential gene expression in Gram-
negative and Gram-positive sepsis in a murine model [74], 
gene expression proﬁ  les in critically ill patients with Gram-
positive and Gram-negative sepsis do not diﬀ  er [75].
Genetic factors related to cytokine expression may also 
inﬂ  uence outcomes. Patients with pulmonary sepsis who 
were found to have a speciﬁ  c CGG haplotype associated 
with low IL-10 production demonstrated signiﬁ  cantly 
higher mortality than patients who had alternative hap-
lotypes [76]. Th  is higher mortality was not seen with 
other sources of infection. Polymorphisms in the human 
genome within the genes that regulate early signal trans-
duction events of the innate immune response, including 
Mal [77], IRAK-4 [78], and MyD88 [79], all increase the risk 
of invasive bacterial pneumonia. Mutations and polymor-
phisms in the human genome to complement systems [80], 
to mannose-binding lectin systems [81], and to the coagu-
lation and ﬁ  brinolytic systems [82,83] also alter the risk and 
prognosis of invasive bacterial pneumonia. Undoubtedly, 
more genomic evidence of disease risk, treatment response, 
and prognosis in CAP will become available as functional 
genomics and transcriptomics becomes the standard of 
care in critical care units in the near future.
Th  e technology of proteomic proﬁ   ling is becoming 
cheaper and is reaching the stage of clinical feasibility 
for large interventional trials. At present, however, little 
information is available about proteomics in clinical trials 
in CAP. Several such studies are ongoing and the results 
will be of considerable interest.
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Discussion and conclusion
In clinical infection, there is a highly variable interaction 
between microbes, their toxins, and the host response. 
Th  e complexity that emerges cannot be represented by 
a single biomarker, let alone a single measurement of a 
biomarker. For example, one PCT value – however low – 
should not be grounds for ruling out antibiotic therapy in 
an adult patient with suspected CAP. PCT is not a marker 
of very early infection – that is, it increases about 6 hours 
after a stimulus [22] – underlying the importance of re-
measurement. A single value on admission (in contrast to 
serial measurement showing changes in PCT with time) 
is not a good indicator of prognosis. A high PCT and 
an increase for 1 day is an early indicator for mortality 
in ICU patients [52]. Th   e information that such markers 
provide must be interpreted with caution and in context. 
Markers should be considered only in conjunction with 
clinical history and examination, and in the light of expe-
rience. Furthermore, a complete knowledge of the biol-
ogy, strengths, and limitations of the marker is important 
before using it as a routine clinical tool.
It is also important to note that markers may be inﬂ  u-
enced by therapy. Immunoactive agents such as steroids 
are frequently used in acutely ill patients and are not nec-
essarily taken adequately into account when measuring 
biomarkers. Administration of steroids is known to aﬀ  ect 
levels of cortisol, for example. Th   is steroid eﬀ  ect may be 
true of other markers, including natriuretic peptides, 
although the evidence for this presently comes from an 
endotoxemia model in healthy subjects rather than from 
patients with CAP [16]. PCT, however, seems not to be 
aﬀ  ected by steroids. A Japanese study shows that PCT has 
good speciﬁ  city in distinguishing acute bacterial infec-
tions from disease ﬂ  are in patients with autoimmune dis-
eases even when they are taking steroids [84]. Th  e  same 
seems to be true for CRP [17]. Markers may also be inﬂ  u-
enced by renal function. Uremia in patients with end-
stage renal disease seems to increase PCT levels, and the 
PCT levels declined after each hemodialysis session [85]. 
Accordingly, cutoﬀ   levels to diagnose bacterial infection 
may have to be adapted in patients with renal dysfunction 
[86].
Th   e future may lie in combining information from sev-
eral markers, each reﬂ  ecting a diﬀ  erent aspect of disease. 
Such a panel might include one marker of bacterial infec-
tion, one marker reﬂ  ecting disordered coagulation, one 
Figure 2. Algorithm for antibiotic therapy in patients with lower respiratory tract infections. Clinical algorithm for the diagnostic work-
up and guidance of antibiotic therapy in patients with lower respiratory tract infections (LRTI). ARDS, acute respiratory distress syndrome; CAP, 
community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; CURB, Confusion, Urea, Respiratory rate, Blood pressure; GOLD, 
Global Initiative for chronic destructive Lung Disease; ICU, intensive care unit; PSI, pneumonia severity index.
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hormone, and one proinﬂ  ammatory cytokine. Th  is pro-
posal draws plausibility from evidence for the incremental 
value of combining markers of left ventricular dysfunc-
tion, myocardial cell damage, renal failure and inﬂ  amma-
tion in predicting cardiovascular deaths among older men 
[81,87]. Incorporating the four biomarkers signiﬁ  cantly 
improved the prognostic value of a model based only 
on established risk factors such as age, blood pressure 
and hyperlipidemia. Interestingly, two of the four mark-
ers involved in predicting cardiovascular risk (pro-brain 
natriuretic peptide and CRP) overlap with those discussed 
above in the context of severe CAP.
It is also relevant to note that a marker valid for one pur-
pose – such as diagnosis – may not be the most helpful in 
establishing a prognosis or in aiding particular therapeu-
tic decisions. PCT, for example, has proven value in ruling 
out nonbacterial causes of inﬂ  ammation and in guiding 
antibiotic use; however, a single measurement of PCT on 
admission is possibly not as predictive of mortality risk as 
a single measurement of proADM or cortisol in patients 
without steroid pretreatment.
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